posted
the cycle has started again...CLBE now at its low and just like the last two years will probably bounce back into the teens and the CEO made it clear the company WILL BE PROFITABLE this year and thats all divisions and now with MDSP involved and their CEO Paul Smith stating they too will be dealing with Calbatech thru the Solena umbrella then CLBE is bound to be heading much much higher especially since there are expected to be over 4000 spa's opening and CLBE announced they expect to bring in $100 million dollars a year in the near future from this division.
CalbaTech's Chief Medical Officer at LifeStem, Inc., Dr. Jason Van Tassel, Interviewed at WallSt.Net
posted
I still feel quite confident that CLBE will seriously break out when least expected.The OS has remains constant for over 3 quarters and the floats is drying up and with insiders locking down over 25% of the total it takes very little to move this at all....I am also expecting an announcement concerning at least 2 patent approvals but there may be a third.CLBE may also have found the partner for the device manufacturing which I believe is a big board public company....we should see soon imo.
CalbaTech acquired KD in the last quarter of 2004. This acquisition substantially increased both product range and revenue in the Research Reagents Division. The product ranges of KD and Molecula are highly complementary, with little over lap. A strength of KD is in the supply of specialized media for culture of model research organisms such as bacteria, yeast, insects and mammalian cell lines. It also supplies products to approximately 300 National Institutes of Health ("NIH") laboratories, contracts invaluable for establishing new products in a favorable government setting. Its secondary products are related to molecular biology reagents. Conversely, Molecula's primary focus is in the design and supply of high value molecular biology reagents such as siRNA and DNA antisense oligonucleotides. It also has reagents such as IPTG that are complementary to customized media. KD believes that the addition of new product lines could significantly increase its revenues within the NIH, to as much as $5 Million annually, within the next five years. A large proportion of molecular biology research depends upon culture of a model organism (bacteria, fruit fly, etc.), which is genetically manipulated by transfection of customized oligonucleotides (siRNA). Thus, an alliance of KD and Molecula will be well placed to provide a competitive single source for these culture media transfection reagents and specialized modifier molecules such as siRNA. Further, as explained above, KD's long standing and trusted position, as a major in-house supplier to NIH will greatly ease entry of Molecula's siRNA into that major market. Please see www.kdmedical.com.
CUSTOMERS
KD Medical and Molecula service five distinct customer types: 1) Federally funded research centers such as the National Institutes of Health, the Naval Medical Center, and the National Cancer Institute; 2)Federally funded "Supply Stores" such as at the National Institutes of Health; 3) University and private research centers such as Glaxo Smith-Kline, Johnson & Johnson, Merck & Co., Pfizer Research, and Wyeth Pharmaceuticals; 4) Medical distributors such as Fisher Scientific and VWR International; and 5) OEMs such as Genetix, Ltd. and PML Microbiologicals, Inc.
MARKET SIZE
The general laboratory supplies industry is 12 to $14 Billion, and the molecular biology market to which the Company provides products and services for medical research and drug discovery on which billions of dollars are spent each year. Specifically, the molecular biology market is approximately $600 Million per year, and the RNAi market is estimated to be $328 Million by 2010.
FINANCIAL PROJECTIONS
The Reagents Division has two companies with combined 2005 revenues of approximately $1.225 Million in gross revenues. CalbaTech believes that combined revenues within the division will be $1.5 Million in 2006. Within three years, it is anticipated that revenues will grow to $5 Million.
PATENTS AND PROPRIETARY TECHNOLOGY
It is the Company's intention to protect its proprietary property through the filing of U.S. and international patent applications, both broad and specific, where necessary and reasonable. The Company believes it will attain strong and broad patent protection for its technologies. It is the Company's intention that all its products be protected under various pending patents, issued patents, copyrights and trademarks.
The Company has the policy of disclosing its proprietary information only under a Confidentiality Agreement. This Agreement has a special clause regarding ownership by the Company of all inventions related to, or based in any way upon, the Company's technologies.
Everyone expects political commercials to oversimplify things, but American commercials dealing with stem cell research make mere oversimplification look like a PhD dissertation. Scepticism that therapeutic cloning might not deliver the goods is interpreted as despicable Pharisaism.
In the weeks before the November 7 elections, the most egregious example of dumbed-down argument uses three actors. There's a teenaged boy who says he might get paralysed in a car accident, a young woman who worries about getting Alzheimer's, and a little girl who pouts that she might get diabetes. "Maybe I'm your mother. Maybe I'm your grandson. Maybe I'm your little girl... How come he think he gets to decide who lives and who dies? Who is he?" It's cloyingly, shamefully, deceitfully emotional, uncontaminated by a smidgen of fact, the medical counterpart of the notorious Willie Horton commercials which sank Michael Dukakis in the 1988 presidential election. But it works.
It works so well, in fact, that it is being used in not one, but four states. A Democratic lobby group, Majority Action, is using it to "turn a powerful spotlight" on four members of the House of Representatives: Jim Walsh, of New York; Chris Chocola, of Indiana; Doug Sherwood, of Pennsylvania; and Thelma Drake, of Virginia. Majority Action spokesman Mark Longabaugh, says that "stem cell research offers great medical hope for patients and families suffering from devastating illness or injuries. This ad, in very powerful terms, lays out what is at stake in the stem cell debate... Republicans have made choices that pick ideology over life-saving medical research."
The only problem is that this medical research hasn't actually saved any lives and may never save any. [SIZE="4"]In fact, the smart money is on adult stem cells[/SIZE]. As Associate Professor James Sherley, of the Massachusetts Institute of Technology, wrote last week: "Despite similar misinformation to the contrary, [SIZE="4"]adult stem cell research is a viable and vibrant path to new medical therapies. Even calling them an alternative to embryonic stem cells misinforms the public. Why? Because embryonic stem cells provide no path at all. [/SIZE]" Even scientists who are ardent supporters of the research have acknowledged that useful products from embryonic stem cells are at least 15 years away. And no one has ventured to guess how much these cures might cost.
Distorted as they may be, something can be learned from ads like these. Take this one from a Congressional race in Wisconsin designed to kneecap Republican John Gard. The music is a bit odd -- what does Enya have to do with stem cells? -- but the ad is quite effective. It cites Republican favourites like Orrin Hatch and Nancy Reagan who back the research, juxtaposing them with Darth Vaders from "the extreme right" like disgraced Congressman Tom Delay, TV evangelist Pat Robertson and Focus on the Family president James Dobson. Gard's ethical reservations would stifle hope for a range of diseases, the ad suggests. These include Alzheimer's, which most scientists acknowledge is probably beyond stem cell cures.
This ad employs clever rhetorical jiujutsu to trip up opponents with the force of their own arguments. Dobson, for instance, is quoted as saying, "Lowering that standard is also likely to lead to human cloning and harvesting of body parts conceived for this purpose." But thumping the drum of doom doesn't work; it only makes him look ridiculous, at least to viewers in the Badger State.
Similarly, the Wisconsin race for governor pits incumbent Jim Doyle against Mark Green, who this woman says is "too extreme" for the job because he opposes stem cell research. (Governor Doyle, on the other hand, is extremely generous. He recently handed over US$1 million to a private company started by the scientist who first isolated human embryonic stem cells, James Thompson.)
Extremism in defence of embryos may be no vice, but it is not necessarily effective. What Dobson says could come to pass, but what he foresees is only on the radar of the best-informed participants in the debate. Meanwhile, his opponents simply ridicule him as Chicken Little.
posted
these .03's will not last as many can already see,I am telling you if you can get any here then you definitely should!! anyone who knows CLBE knows whats coming!
posted
the previous post and this one both came from another site by very good analyst.
Originally Posted by JRW This company has been known to release information over the Christmas Holidays in the past. Look what they released in December last year. If they release financials in December, I'll be preparing for a December run.
CALBATECH INC Files SEC form 8-K/A, Financial Statements and Exhibits EDGAR Online (Wed, Dec 28) • CALBATECH INC Files SEC form 10KSB/A, Annual Report EDGAR Online (Wed, Dec 28) • CALBATECH INC Files SEC form 8-K, Entry into Material Agreement EDGAR Online (Fri, Dec 23)
Originally Posted by stocks1984 Then your bet is headed the right direction. On my chart analysis from last night. I stated that the run comes on the last week before the month of the POP. DEC. it the 5th month were the stock dips and the last week of dec. is when it will start to go up into january.
posted
not sure this is it yet but I do feel like this is an insider info leak like happened last year when CLBE ran from the .025 level to .14. The company has so much more now then it did then and I think this time it will not drop back the same once it runs.
posted
I bet tomorrow and the rest of this week will be real interesting and probably even more so into the last week of the year....if all remains consistant we should get a filing before year end.
posted
it seems like Allstocks has slowed down a little lately.IMO this is still one of the best message boards out here,it just may need a little more attention.
posted
I'm here with you Quest. I've been accumulating and flipped for awhile. I have more shares now than when I started (and they are all free), Monday and Tuesday was a pure gift!
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
posted
now thats how you trade Squire and since we have stated many times that CLBE is definitely a fundamental play then trading for freebies and holding a core position will certainly pay off.
by Steven Ertelt LifeNews.com Editor December 19, 2006
Cambridge, England (LifeNews.com) -- A leading British scientist who has engaged in stem cell research says the benefits of human cloning for research are being oversold. Professor Austin Smith of the University of Cambridge says research cloning may never lead to cures and that scientists should focus more on adult stem cell research.
Professor Smith told the local Times newspaper that human cloning for research purposes "clearly upsets the general public" and has limited potential for treating diseases. It also adds little to the understanding of human biology, he said.
Smith also indicated that one of the biggest reasons for creating cloned human embryos -- to eventually yield patient-specific embryonic stem cells that would overcome immune system rejection issues -- may never come to fruition.
Instead, Smith said scientists should spend more time focusing on adult stem cell research or using embryonic stem cells from leftover human embryos from fertility clinics.
Such research has not been given enough attention, he told the Times, but would likely be more beneficial for patients in the long-term.
Smith is also concerned that some cloning experiments are simply being performed out of intellectual curiosity without any real tangible benefit intended.
"Its prominence is out of proportion to the significance of what's being done, and there are real question marks about whether it has any utility at all," he told the newspaper.
Smith will be the new director of the Wellcome Trust Center for Stem Cell Research in Cambridge, which opens on Monday. He previously was a leader at University of Edinburgh's Institute for Stem Cell Research, where Dolly the sheep was cloned.
In June, a team Smith led discovered a gene that may make it possible to take adult stem cells and transform them into embryonic ones with the same properties. If their research proves to be a success, it could greatly impact the debate about embryonic stem cell research by reducing the need to use it or human cloning for studies.
The scientists used mouse cells to examine the role of a gene that, when fused to a specialized brain adult stem cell reprograms it into an embryonic one. Ultimately, a patient's own stem cells could be turned into embryonic ones and reinserted into their bodies to cure or heal various ailments.
Smith told the San Francisco Chronicle at the time that at least another year of experimental work is needed to understand the reprogramming process, which involves a gene known as "nanog."
"We thought this was something that would take us a very long time to work out, but now this changes from being a black box to something we can work to understand," he said.
Pro-life groups oppose embryonic stem cell research because days-old unborn children are killed for their stem cells. They say adult stem cell research has been successful on its own because it has already produced dozens of cures and treatments.
posted
thats OK stocktrader we all can have differant opinions and many traders should be skeptical when playing the pennies......thats where deep DD really helps make my decisions on which stocks to invest in and which to trade.
posted
CalbaTech Announces Increase in Revenue for Nine Months; LifeStem Continuing to Enroll New Medspas to Sell Its Stem Cell MicroBank(TM) Service
- $3.58 Million Projection for Revenues for First Year Banking Services -
IRVINE, Calif., Nov 15, 2006 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech and pharmaceutical research markets and to academic institutions, today announced that revenues for the first nine months ended September 30, 2006 totaled $977,444, up three percent compared to the same period in 2005. Net income for the first nine months of 2006 totaled $629,822, or $0.01 per share, compared to a loss in 2005. The net income reported is because of the unrealized gain on adjustment of derivative and warrant liabilities to fair value of the underlying securities relating to the convertible notes CalbaTech obtained in 2005. CalbaTech posted a gross profit of $579,443 for the nine month period, compared to a gross profit of $449,330 for the first nine months of 2005.
The Company also announced a significant decrease in operating expenses, from $1.72 million for the nine months ended September 30, 2005 to $1.33 million for the same period in the current year. "We continue to be successful in cutting costs and increasing profitability," said James DeOlden, CEO.
In its Form 10-QSB filing, CalbaTech said its wholly-owned subsidiary, LifeStem, (www.life-stem.com) has moved ahead with its roll-out of the Stem Cell MicroBank(TM) Service, collecting adult stem cells for possible future needs, through the Solana Medspas network. LifeStem has begun marketing its service, providing marketing materials to the individual medspas, and has begun providing training to the medspa personnel. In a major positive development, Solana Medspas has entered into a letter of intent with a partner to open 4,000 additional medspas throughout the country within the next four years, all of which potentially would carry LifeStem's banking services.
"LifeStem is conservatively projecting $3.858 million in revenues in the first 12 months of operation and $26.3 million during its second 12 months," Mr. DeOlden said. "While we have not processed any clients yet, it is not because of lack of interest. We have received requests for subscription packets, have begun hosting seminars to potential clients, and our Chief Medical Officer, Dr. Jason Van Tassel, M.D. appeared on the radio and the Internet to discuss our service to a significant listening audience. Some of the regulatory, logistical and training issues have taken longer than anticipated, but this is to be expected in a new breakthrough service such as ours."
Mr. DeOlden continued, "The therapeutic possibilities that may be provided by collecting and preserving healthy adult stem cells on a pre-disease basis could revolutionize the practice of medicine. The market for stem cell technology has been estimated to grow to $30 billion by the year 2010."
I would say that the MMs have no choice tomorrow. One of the main reasons is because the company has barely increased the share count for nearly a year:
This afternoon, I had a long converstation with Jim Parrott, Cheif Operating Officer at Solana MedSpas. Solana and LifeStem have full regulatory approval for California and are working on gaining approval for other states. Getting regulatory approval must be done on a state by state basis and takes some time. There are also viability issues in the process as there are 4 collections taken, three from blood and one from adipose tissue (fat cells). The samples are then sent to Cryogenics to be preserved. All of this had to be done many times to satisfy the requirements for the State of California. There are currently 2 open MicroBank locations, one in Irvine, one in Pasadena. There are also 8 MicroBanks currently in progress in the State of California. Solana currently has 32 MedSpas open in 17 states. They are opening 2-3 new MedSpas per month and anticipate hitting the 100 location mark in 2008. The company feels that a population over 150,000 should be able to support one spa. There has been very positive reception of the LifeStem service from MedSpa owners. The additional equipment to add the MicroBank service is around $500 and the MedSpa recieves an exclusive LifeStem territory. This means that outside of training for LifeStem specifically, every MedSpa can offer the service. Rough averages for a MedSpa include around $250 spent per visit, 3-5 visits per person per year. A MedSpa in a decent location (all of them currently as there are only 32) will grow their customer base to 750-1500 clients in their first year.
posted
IRVINE, Calif.—In mid-August, LifeStem Inc., a subsidiary of CalbaTech Inc., intro*duced a program that collects and banks adult stem cells from two tissue sources in healthy individuals. James DeOlden, CEO of CalbaTech, says LifeStem’s “Stem Cell MicroBank Service retrieves stem cells from two tissue sources, peripheral blood and adipose tissue. Stem cells are extracted from each individual collection and stored cryogenically.” Three collec*tions of blood and one collection of adipose tissue, he says, cost $3,500; annual storage fees are $200.
All cells placed in the MicroBank are for autologous use if a client becomes sick and can benefit from stem cell-based ther*apies, says DeOlden, though one potential exception would be if clients designate that CalbaTech may provide a portion of their stem cells for research purposes, in exchange for a discount on MicroBank services.
Thanks to Proposition 71, which funds stem cell research in California, DeOlden sees opportunity to sell research-grade stem cells to local scientists and avoid shipping cells outside the state. CalbaTech already collaborates with stem cell ther*apy companies, says DeOlden. LifeStem expects to bank more than 1,000 dona*tions during the program’s first year, says DeOlden. “We believe that our banking provides the best opportunity for those who wish to bank and benefit from research activity within the indus*try due to the fact that we collect stem cells from two tissue sources, thus doubling the potential thera*peutic applications.”
LifeStem cites heart, liver, bone, and mus*cle as some of the tissues that the extracted stem cells could generate. A recent prepared statement from CalbaTech cited research reported on Cell.com suggesting that cells collected for the MicroBank could potentially be manipulated to mir*ror embryonic stem cells, but with*out tissue rejection concerns.
CalbaTech will supplement its core revenue through the MicroBank, which it projects to earn $3.9 million during the program’s first year, while other subsidiaries, such as Molecula and K-D Medical, will continue to sell research supplies like oligo*nucleotides, buffers, reagents, and growth media. CalbaTech, says DeOlden, “determined early on to not just be seen as an R&D com*pany, so we sought out other com*panies that had revenue, that had a business model that made sense to us, and acquired a couple of com*panies on the east coast.” Having resources within CalbaTech, he believes, will make it easier to sup*ply cell expansion operations aris*ing from the MicroBank.
Although Shankar Sellappan, a research analyst in drug dis*covery technologies at Frost & Sullivan, cites other companies selling robust stem cells, he says, “The business of banking seems like a very niche market. It seems like a neat business. I don’t know how much it will grow.” He sees low storage costs as a plus, though, and LifeStem’s agreement with Solana MedSpa locations, which will serve as MicroBank dona*tion points throughout the United States, should reach customers with disposable income.
Sellappan agrees that adult stem cells show potential for therapies beyond current uses but cau*tions that generating enough cells can require time and specialized environments, making their use difficult after emergencies. Even if the right types of tissues are generated, some, like heart cells, which have difficulties meshing because they must beat in rhythm, are problematic. Despite current hurdles, Sellappan sees numer*ous future markets for stem cells, including adipose applications in reconstructive, plastic, and breast enhancement surgeries.
LifeStem Inc., a subsidiary of CalbaTech, Inc., offers a proprietary method of stem cell banking which allows healthy individuals to collect and store their own stem cells for possible future therapeutic use.
Our patent-pending Stem Cell MicroBank™ Service provides you with a clear advantage. Unlike technologies that harvest stem cells from a single tissue source, LifeStem’s Stem Cell MicroBank™ process works by collecting and storing stem cells derived from two stem-cell rich sources: blood and adipose tissue. The reason? Each type of stem cell has different characteristics and will naturally grow and develop into different types of healthy tissues. Depending on your future health and wellness needs, having a choice between the two different stem cell populations could make all the difference in the success of your future treatments! Expand your options---use multi-sourced stem cell banking today!
WHAT ARE ADULT STEM CELLS?
Adult stem cells are unique, undifferentiated cells, known as “master cells” for their ability to repair, renew and regenerate the tissues in which they reside. Adult stem cells can be found among the mature cells of the brain, bone marrow, the blood and blood vessels, skeletal muscle, fat, skin and liver.
Classifications of stem cells are based upon their ability to transform (differentiate) into different cell types. For example, those known as “hematopoietic stem cells”, found primarily in blood, give rise to many of the body’s organs and tissues, including all of the cells found in the blood, i.e.; in red blood cells, white blood cells and platelets, as well as in skeletal muscle cells, heart muscle cells and liver cells. The adult stem cells that are found in fat, or adipose tissue, give rise to structural tissues of the body such as bone, muscle, cartilage, and vessels.
THE STEM CELL MICROBANK™ SERVICE
Each stem cell sample is immersed in the protective solvent dimethylsulfoxide (DMSO) prior to being stored in LifeStem’s liquid nitrogen cryopreservation freezers. The liquid nitrogen freezes the cells at a temperature of - 196° C, which effectively stops all cellular metabolic processes. The cells’ “biological clock” stops ticking and the cells are “suspended in time” until thawed, thus preserving their health and usefulness for possible future applications.
Why Bank Now? The promise of adult stem cell therapies is an exciting one with the imminent development of new clinical applications! Don’t wait, bank now while your cells are healthy and vital.
Cost: The cost of the entire service is $3,500 which includes the first annual storage fee of $200. In subsequent years you will be billed for the storage fee. Interest free financing is available.
THE PROMISE OF ADULT STEM CELL THERAPIES
You Have Now Entered the World of Stem Cells!
The promise of adult stem cell therapies is an exciting one! One of the most exciting new medical technologies that may hold the key to fighting aging and disease could lie within our own stem cells and their ability to repopulate and replace cells that have been damaged by the aging process, disease or injury. The Stem Cell Research Foundation aptly refers to stem cell therapy as a “revolution in medicine”. Medical professionals see preserved stem cells as a new source of cells that can be used in the rebuilding and repair of the body’s tissues, organs, even the immune system. In fact, “stem cell therapy techniques are being applied experimentally to a wide range of human disorders, including many types of cancer, neurological diseases such as Parkinson’s disease, ALS (Lou Gehrig’s disease), spinal cord injuries, heart disease, liver disease, muscular dystrophy, stroke and diabetes. Even blinding diseases of the retina may someday be cured by replacing dead retinal cells with new ones!” Consider this…the stem cells that you choose to preserve today, could be used to return the gift of life and health tomorrow!
What You Should Know About Stem Cell Therapies
Although much of the work in the field of stem cell therapy is still largely experimental, applications of this technology have been in use for years. For example, a bone marrow transplant is the most common type of stem cell therapy, one in which the stem cells in a donor’s marrow are used to replace the blood cells of the victims of leukemia and other cancers. Cell therapy is also being tested to graft new skin cells for burn victims and to regenerate corneas for those that are sight-impaired. In a recent advance, pancreatic cells were implanted into the body of a diabetic and began producing insulin!
posted
Irvine, CA (PRWeb) February 7, 2007 -- John Buckingham, CEO and co-founder of Solana MedSpas, has released his comments on the state of the Medical Spa Industry. Solana MedSpas, based in Irvine, Calif., is the nation's leader in Medspa development, with 116 locally branded Medspas open or opening in 30 states.
"According to the International Medical Spa Association (IMSA), the Medspa movement has been closely linked to the growing baby boomer generation in the United States, consisting of persons born during the post-World War II birth rate boom from 1946 - 1964," Buckingham notes.
"Baby boomers are the wealthiest, best educated and most sophisticated consumers in history and at 78 million strong, they are the single largest consumer group in the U.S. today. They currently make up 51 percent of the total U.S. population and control 75 percent of this country's wealth. IMSA statistics indicate that 12,000 Americans turn 50 every day (1 every 8 seconds) and this will continue for the next 20 years. Americans over 55 will grow by 60 percent in the next 20 years and their buying power will exceed $2 trillion in 2007.
[SIZE="7"][COLOR="Red"]buying power will exceed $2 trillion in 2007.[/COLOR][/SIZE]
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
